The global immune thrombocytopenia drugs market size will grow by USD 919.81 million during 2019-2023 at a CAGR of almost 5%. The high prevalence of associated risk factors for immune thrombocytopenia and the development of biosimilars are some of the factors expected to drive market growth. This market report provides a detailed analysis of the market by product (TPO-RAs, corticosteroids, IVIGs, and other drugs) and geography (Asia, Europe, North America, and ROW). Also, the report analyzes the market’s competitive landscape and offers information on several market vendors including Amgen Inc., CSL Ltd., Horizon Therapeutics Plc, Merck & Co. Inc., Novartis AG, and Rigel Pharmaceuticals Inc.
Key Insights from Immune Thrombocytopenia Drugs Market – Global Forecast 2019-2023
See the complete table of contents and list of exhibits, as well as selected illustrations and example pages from the immune thrombocytopenia drugs market report.
End-users prefer biosimilars over biologics because of their low cost. The low cost of biosimilars can be attributed to the fewer number of clinical trials required for approval. The upcoming expiration of patents in the immune thrombocytopenia drugs market will fuel the development of biosimilars for those products. For instance, the forthcoming expiration of patents of Nplate (romiplostim) and rituximab has encouraged market vendors to develop their biosimilars. This will also create several opportunities for new vendors to enter the market. Hence, the growing popularity and development of biosimilars will augment the growth of the immune thrombocytopenia drugs market throughout the next five years.
Young women and people who have rheumatoid arthritis, lupus, and antiphospholipid syndrome are highly susceptible to immune thrombocytopenia. Immune thrombocytopenia may be caused by human immunodeficiency virus (HIV) and hepatitis infections in adults while the disease may occur after a viral illness such as mumps or flu in children. The high prevalence of such diseases and infections across the world will increase the chances of immune thrombocytopenia. As a result, the demand for treatment options and drugs to cure immune thrombocytopenia will also grow. The high prevalence of associated risk factors for immune thrombocytopenia will be one of the significant factors responsible for the growth of the market at a CAGR of almost 5% during the forecast period.
Market size for 2018
Market forecast for 2019 to 2023
Regional market opportunities
Market segment opportunities
Growth momentum: Overall market and individual market segments
Market condition: 2018
Market segmentation based on product: TPO-RAs, corticosteroids, IVIGs, and other drugs
Market size, market forecast, and growth momentum
Market size and forecast in Asia, Europe, North America, and ROW
Market forecasts for key countries
Porter’s Five Forces analysis
Trends, drivers, and challenges
Criticality of inputs
Factors of differentiation
Market landscape disruption
Factors driving disruptions
Market positioning of vendors
Sources of disruption
The product segment has been segregated into TPO-RAs, corticosteroids, IVIGs, and other drugs. The TPO-RAs segment accounted for the highest immune thrombocytopenia drugs market share in 2018. During the forecast period, this segment will grow at a faster pace than the overall market. The corticosteroids and IVIGs segments will grow at a slower pace than the overall market.
The increasing demand for approved drugs over off-label corticosteroids will be one of the significant factors fueling immune thrombocytopenia drugs market growth in this segment.
North America accounted for the highest market share in 2018. The market’s growth in this region will be faster than the growth of the market in other regions and will account for the largest immune thrombocytopenia drugs market share throughout the forecast period. The US is a key market for immune thrombocytopenia drugs in North America.
High prevalence of associated risk factors and the increasing sale of approved drugs for the treatment of immune thrombocytopenia in North America will contribute to the growth of the immune thrombocytopenia drugs market in this region.
Top Immune Thrombocytopenia Drugs Companies
The global immune thrombocytopenia (ITP) drugs market is fragmented. To help clients improve their position, this immune thrombocytopenia drugs market analysis report provides information on the competitive landscape and the products offered by various companies. Moreover, this immune thrombocytopenia drugs market research report also includes information on the upcoming trends and challenges that will influence market growth. This will help companies create strategies to make most of the upcoming growth opportunities.
The report offers a detailed analysis of several leading immune thrombocytopenia drugs manufacturers, including:
Horizon Therapeutics Plc
Merck & Co., Inc.
Rigel Pharmaceuticals Inc.
Segments Covered in the Report
Immune thrombocytopenia drugs market by product
Thrombopoietin receptor agonists (TPO-RAs)
Intravenous immunoglobins (IVIGs)
Immune thrombocytopenia drugs market by region
Key Highlights of the Immune Thrombocytopenia Drugs Market Forecast Report for the Period 2019-2023
CAGR of the market during the forecast period 2019-2023
Detailed information on factors that will accelerate the growth of the immune thrombocytopenia drugs market size during the next five years
Precise estimation of the global ITP drugs market size and its contribution to the parent market
Accurate predictions on upcoming trends and changes in consumer behavior
The growth of the immune thrombocytopenia drugs industry across Asia, Europe, North America, and ROW
A thorough analysis of the market’s competitive landscape and detailed information on several vendors
Comprehensive details of factors that will challenge the growth of immune thrombocytopenia drugs companies
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch